Tuesday, January 14, 2014

Bristol-Myers Ties Hepatitis C Success to Gilead’s Sovaldi

Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill
Its Back: Daclatasvir Plus Sofosbuvir-Three HCV Clinical Trials Sponsored By Bristol-Myers Squibb 

Investment Commentary
Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill
Bristol-Myers Squibb Co. (BMY) will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc. (GILD)’s approved pill... 
Bristol-Myers is seeking European approval of its drug, daclatasvir, and wants to pair it with Gilead’s Sovaldi before Gilead gains clearance for its second hepatitis C treatment. The companies will do the same in the U.S. if they can get a broad approval from regulators, said Charles Bancroft, the chief financial officer for Bristol-Myers, in an interview at the JPMorgan Chase & Co. health-care conference in San Francisco...

Read more here.....

To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net

No comments:

Post a Comment